Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05977881 · ClinicalTrials.gov registry record · NA
Substance Checking Outreach and Pre-Exposure Prophylaxis (PrEP) Engagement Study
A NA study of HIV Infections, sponsored by Johns Hopkins Bloomberg School of Public Health.
- Recruiting
- Registry status
- NA
- Development phase
- 500
- Enrollment target
- 1
- Study location
NCT05977881: Recruiting NA study of HIV Infections, sponsored by Johns Hopkins Bloomberg School of Public Health.
NCT05977881 is a NA study of HIV Infections that is actively recruiting participants, run by Johns Hopkins Bloomberg School of Public Health. The registered enrollment target is 500 participants, above the 445-participant average among 542 other HIV Infections trials with a reported enrollment target (12% higher). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05977881, a NA study of HIV Infections, is actively recruiting participants, sponsored by Johns Hopkins Bloomberg School of Public Health.
- RECRUITING
- Registry status
- NA
- Development phase
- 500 participants
- Enrollment target
- 1
- Study location
Study Summary
Through the proposed Substance Checking Outreach and Pre-Exposure Prophylaxis (PrEP) Engagement (SCOPE) study, the investigators will design and evaluate an overdose prevention and HIV prevention study among people who use drugs (PWUD). Specifically, SCOPE will provide access to drug-checking services for PWUD to better understand the contents of the drug supply, in combination with PrEP for those who are HIV-, to both reduce overdose and HIV among PWUD in Baltimore City.
Primary Outcome
Investigators will measure current PrEP status by assessing participant self-report using an internally developed questionnaire. Change in current PrEP status will be measured using three survey items asking participants 1) if they are currently prescribed either form of PrEP (pill form or injection), 2) currently taking/not taking the prescription, and 3) which type/brand of PrEP are they currently taking. The response range options for current prescription and currently taking PrEP are binary
Conditions Studied
Interventions
- OTHER CHECKIT!
Study Locations (1)
Maryland
- Johns Hopkins School of Public Health - Baltimore
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 500 participants |
| Start Date | 2023-07-28 |
| Est. Completion | 2026-06-30 |
| Phase | NA |
What NCT05977881 shows while recruiting
NCT05977881 is an interventional study that assigns participants to a tested intervention. The registered 500 participants enrollment target is mid-sized for trials with a published cap, above the 445-participant average among 542 other HIV Infections trials with a reported enrollment target (12% higher).
The record links to 1 condition, with HIV Infections appearing as the primary indexed condition, and to 1 intervention - of which CHECKIT! is the first listed.
NCT05977881 reports a single indexed study location in Maryland.
Frequently Asked Questions
What is clinical trial NCT05977881 about?
NCT05977881 is a clinical study titled "Substance Checking Outreach and Pre-Exposure Prophylaxis (PrEP) Engagement Study". Through the proposed Substance Checking Outreach and Pre-Exposure Prophylaxis (PrEP) Engagement (SCOPE) study, the investigators will design and evaluate an overdose prevention and HIV prevention study among people who use drugs (PWUD). Specifically, SCOPE will provide access to drug-checking servic...
What is the current status of trial NCT05977881?
This trial is currently recruiting. It is a NA study. The enrollment target is 500 participants. The study started on 2023-07-28. Estimated completion is 2026-06-30.
What conditions does trial NCT05977881 study?
This clinical trial studies the following conditions: HIV Infections.
What interventions are being tested in trial NCT05977881?
The interventions under investigation include: CHECKIT! (OTHER).
Who is sponsoring clinical trial NCT05977881?
This trial is sponsored by Johns Hopkins Bloomberg School of Public Health, which has 187 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05977881 being conducted?
This trial has 1 study location across Maryland. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for HIV Infections
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT05977881's enrollment target sits among peer trials
500 62nd of 542 higher than 479 of 542 other HIV Infections trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other HIV Infections trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
TRAC-ER Intervention to Reduce Risky Alcohol Use and HIV Risk
RECRUITING · NA
-
Community-based Education, Navigation, and Support Intervention for Military Veterans
RECRUITING · NA
-
WiseApp for Spanish Speakers Living With HIV
RECRUITING · NA
-
Comprehensive HIV and Harm Prevention Via Telehealth
RECRUITING · NA
-
Food as Medicine for HIV and Diabetes
RECRUITING · NA
-
Screen Smart: Using Digital Health to Improve HIV Screening and Prevention
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00001230 · 500 participants
Host Response to Infection and Treatment in Filarial Diseases
- NCT00001529 · 500 participants
Improved Methods of Cell Selection for Bone Marrow Transplant Alternatives
- NCT00697411 · 500 participants
Study of Selected X-Linked Disorders: Aicardi Syndrome
- NCT00903110 · 500 participants
Global Patient Registry to Monitor Long-term Safety and Effectiveness of Increlex® in Children and Adolescents With Severe Primary Insulin-like Growth Factor-1 Deficiency (SPIGFD).
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI